These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 11483392)

  • 41. [Axilla skin biopsy in the diagnosis of Lafora's disease].
    Pérez Sempere A; Simón R; Martínez Menéndez B; Torres J; Cabello A; Mateos F
    Neurologia; 1994 May; 9(5):188-90. PubMed ID: 8024824
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Laforin and malin deletions in mice produce similar neurologic impairments.
    García-Cabrero AM; Marinas A; Guerrero R; de Córdoba SR; Serratosa JM; Sánchez MP
    J Neuropathol Exp Neurol; 2012 May; 71(5):413-21. PubMed ID: 22487859
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Relationship between glycogen accumulation and the laforin dual specificity phosphatase.
    Wang W; Parker GE; Skurat AV; Raben N; DePaoli-Roach AA; Roach PJ
    Biochem Biophys Res Commun; 2006 Nov; 350(3):588-92. PubMed ID: 17022935
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A distinct form of adult polyglucosan body disease with massive involvement of central and peripheral neuronal processes and astrocytes: a report of four cases and a review of the occurrence of polyglucosan bodies in other conditions such as Lafora's disease and normal ageing.
    Robitaille Y; Carpenter S; Karpati G; DiMauro SD
    Brain; 1980 Jun; 103(2):315-36. PubMed ID: 6249438
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Progressive Myoclonus Epilepsy in Congenital Generalized Lipodystrophy type 2: Report of 3 cases and literature review.
    Opri R; Fabrizi GM; Cantalupo G; Ferrarini M; Simonati A; Dalla Bernardina B; Darra F
    Seizure; 2016 Nov; 42():1-6. PubMed ID: 27632409
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hepatic disease as the first manifestation of progressive myoclonus epilepsy of Lafora.
    Gómez-Garre P; Gutiérrez-Delicado E; Gómez-Abad C; Morales-Corraliza J; Villanueva VE; Rodríguez de Córdoba S; Larrauri J; Gutiérrez M; Berciano J; Serratosa JM
    Neurology; 2007 Apr; 68(17):1369-73. PubMed ID: 17452581
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The gene for progressive myoclonus epilepsy of the Lafora type maps to chromosome 6q.
    Serratosa JM; Delgado-Escueta AV; Posada I; Shih S; Drury I; Berciano J; Zabala JA; Antúnez MC; Sparkes RS
    Hum Mol Genet; 1995 Sep; 4(9):1657-63. PubMed ID: 8541857
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Alternative splicing modulates subcellular localization of laforin.
    Ganesh S; Suzuki T; Yamakawa K
    Biochem Biophys Res Commun; 2002 Mar; 291(5):1134-7. PubMed ID: 11883934
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bioptically demonstrated Lafora disease without EPM2A mutation: a clinical and neurophysiological study of two sisters.
    Boccella P; Striano P; Zara F; Barbieri F; Sarappa C; Vacca G; de Falco FA; Striano S
    Clin Neurol Neurosurg; 2003 Dec; 106(1):55-9. PubMed ID: 14643920
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lafora disease: epidemiology, pathophysiology and management.
    Monaghan TS; Delanty N
    CNS Drugs; 2010 Jul; 24(7):549-61. PubMed ID: 20527995
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Lafora disease. A new case of confirmation of diagnosis on molecular genetic studies].
    Martínez-Bermejo A; López-Martín V; Serratosa JM; Gutiérrez-Molina M; Gómez-Garre P; Arcas J; Tendero A; Roche C; Pérez-Mies B
    Rev Neurol; 2002 Jan 16-31; 34(2):117-20. PubMed ID: 11988905
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Utilization of skin biopsy for diagnosis in a case of Lafora disease.
    Rozenova KA; Lehman JS; Grande JP; Fine AL; Wieland CN
    J Cutan Pathol; 2022 Oct; 49(10):885-888. PubMed ID: 35708461
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [2 familial cases of Lafora disease. Clinical, electroencephalographic and pathologic study].
    Boudouresques J; Roger J; Khalil R; Pellissier JF; Ali Cherif A; Tafani B; Champion MF
    Rev Neurol (Paris); 1978; 134(8-9):523-40. PubMed ID: 107556
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical and genetic studies in patients with Lafora disease from Pakistan.
    Ahmad A; Dad R; Ullah MI; Baig TA; Ahmad IN; Nasir A; Hübner CA; Hassan MJ
    J Neurol Sci; 2017 Feb; 373():263-267. PubMed ID: 28131202
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Progressive myoclonic epilepsies.
    Conry JA
    J Child Neurol; 2002 Jan; 17 Suppl 1():S80-4. PubMed ID: 11918469
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lafora progressive Myoclonus Epilepsy mutation database-EPM2A and NHLRC1 (EPM2B) genes.
    Ianzano L; Zhang J; Chan EM; Zhao XC; Lohi H; Scherer SW; Minassian BA
    Hum Mutat; 2005 Oct; 26(4):397. PubMed ID: 16134145
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Progressive myoclonus epilepsy in a beagle.
    Gredal H; Berendt M; Leifsson PS
    J Small Anim Pract; 2003 Nov; 44(11):511-4. PubMed ID: 14635965
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of new and common mutations in the EPM2A gene in Lafora disease.
    Minassian BA; Ianzano L; Delgado-Escueta AV; Scherer SW
    Neurology; 2000 Jan; 54(2):488-90. PubMed ID: 10668720
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Suppression of leptin signaling reduces polyglucosan inclusions and seizure susceptibility in a mouse model for Lafora disease.
    Rai A; Mishra R; Ganesh S
    Hum Mol Genet; 2017 Dec; 26(24):4778-4785. PubMed ID: 28973665
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lafora's disease in south India: a clinical, electrophysiologic, and pathologic study.
    Acharya JN; Satishchandra P; Asha T; Shankar SK
    Epilepsia; 1993; 34(3):476-87. PubMed ID: 8389290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.